July 5, 2012
/PRNewswire/ -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the 7th Annual JMP Securities Healthcare Conference on Thursday, July 12 at 10:30 a.m. Eastern Time in New
, and provide a business overview and update.
A live audio webcast of the presentation will be accessible on the Investors page of the Company's website at
. Replays of the presentation will be available at the same location for 90 days following the presentation.
About Optimer Pharmaceuticals
Optimer Pharmaceuticals, Inc. is a global biopharmaceutical company focused on developing and commercializing innovative hospital specialty products that have a positive impact on society. Optimer developed DIFICID® (fidaxomicin) tablets, an FDA-approved antibacterial drug for the treatment of adult patients with
-associated diarrhea (CDAD) and is commercializing DIFICID in the US and
. Optimer also received marketing authorization for fidaxomicin tablets in the European Union where its partner, Astellas Pharma Europe, is commercializing fidaxomicin under the trade name DIFICLIR™. The company is exploring marketing authorization in other parts of the world where
has emerged as a serious health problem, including
. Additional information can be found at
Optimer Pharmaceuticals, Inc.
, VP of Investor Relations and Corporate Communications(858) 964-3418
Jason I. Spark
, Senior Vice President619-849-6005
OPTIMER and DIFICID are trademarks of Optimer Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.
SOURCE Optimer Pharmaceuticals, Inc.